Lake Street Capital Boosts Artivion (NYSE:AORT) Price Target to $30.00

Artivion (NYSE:AORT) had its price target boosted by Lake Street Capital from $28.00 to $30.00 in a research report released on Tuesday morning, Benzinga reports. Lake Street Capital currently has a buy rating on the stock.

Several other equities analysts have also weighed in on the stock. Stifel Nicolaus raised their price objective on shares of Artivion from $22.00 to $25.00 and gave the company a buy rating in a research report on Tuesday, May 7th. Needham & Company LLC upped their price objective on shares of Artivion from $25.00 to $30.00 and gave the company a buy rating in a research note on Tuesday, May 7th.

Artivion Stock Performance

NYSE:AORT opened at $25.85 on Tuesday. Artivion has a twelve month low of $12.16 and a twelve month high of $26.26. The company has a current ratio of 6.04, a quick ratio of 4.26 and a debt-to-equity ratio of 1.07. The company has a 50-day moving average of $23.33 and a 200-day moving average of $20.53. The firm has a market cap of $1.08 billion, a price-to-earnings ratio of -107.71 and a beta of 1.75.

Artivion (NYSE:AORT) last posted its quarterly earnings data on Monday, May 6th. The company reported $0.06 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.04. Artivion had a negative net margin of 2.61% and a positive return on equity of 3.64%. The company had revenue of $97.43 million during the quarter, compared to analyst estimates of $92.30 million. Analysts forecast that Artivion will post 0.24 earnings per share for the current fiscal year.

Institutional Trading of Artivion

A number of hedge funds have recently made changes to their positions in AORT. GAMMA Investing LLC lifted its position in shares of Artivion by 38.6% in the first quarter. GAMMA Investing LLC now owns 1,814 shares of the company’s stock worth $38,000 after purchasing an additional 505 shares in the last quarter. Register Financial Advisors LLC purchased a new stake in shares of Artivion in the first quarter worth approximately $114,000. Allspring Global Investments Holdings LLC lifted its position in shares of Artivion by 291.3% in the first quarter. Allspring Global Investments Holdings LLC now owns 5,580 shares of the company’s stock worth $118,000 after purchasing an additional 4,154 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Artivion by 25.3% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,430 shares of the company’s stock worth $186,000 after purchasing an additional 2,108 shares in the last quarter. Finally, SG Americas Securities LLC lifted its position in shares of Artivion by 7.8% in the fourth quarter. SG Americas Securities LLC now owns 13,393 shares of the company’s stock worth $239,000 after purchasing an additional 968 shares in the last quarter. 86.37% of the stock is owned by hedge funds and other institutional investors.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.